Join
Live feed
·
PRReleasevia Quantisnow
Turning Point Therapeutics Inc. logo

Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines

ByQuantisnow·Wall Street's wire, on your screen.
TPTX· Turning Point Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TPTX (Turning Point Therapeutics Inc.) and more on Quantisnow.